Gilteritinib

Gilteritinib

SCHEMBL21819929

CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

AXLFLT3

The experimentally established mechanism targets of Gilteritinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FLT3 known ✓ P36888 16/20 1.00
▸ AXL known ✓ P30530 1/20 0.92
▸ RET P07949 14/20 1.00
▸ ROS1 P08922 14/20 1.00
▸ EML4 Q9HC35 8/20 0.92
▸ ALK Q9UM73 8/20 0.92
▸ BMPR1B O00238 1/20 0.92
▸ PLK4 O00444 1/20 0.92
▸ CIT O14578 1/20 0.92
▸ AURKA O14965 1/20 0.92
▸ GAK O14976 1/20 0.92
▸ EPHB6 O15197 1/20 0.92
▸ RIPK2 O43353 1/20 0.92
▸ BUB1 O43683 1/20 0.92
▸ SNRNP200 O75643 1/20 0.92
▸ STK16 O75716 1/20 0.92
▸ STK10 O94804 1/20 0.92
▸ MAP4K4 O95819 1/20 0.92
▸ LATS1 O95835 1/20 0.92
▸ EGFR P00533 1/20 0.92

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Gilteritinib SCHEMBL29357951 1.00 FLT3 (1.00) FLT3RETROS1EML4ALK
Gilteritinib SCHEMBL29432551 0.96 FLT3 (1.00) FLT3RETROS1EML4ALK
Gilteritinib SCHEMBL29355822 0.96 FLT3 (1.00) FLT3RETROS1EML4ALK
Gilteritinib SCHEMBL282229 0.96 FLT3 (1.00) FLT3RETROS1EML4ALK
SCHEMBL328303 0.93 FLT3 (0.94) FLT3RETROS1EML4ALK
SCHEMBL29157675 0.92 FLT3 (0.92) FLT3RETROS1EML4ALK
Gilteritinib SCHEMBL22684910 0.91 FLT3 (0.91) FLT3RETROS1EML4ALK
Gilteritinib SCHEMBL22684912 0.91 FLT3 (0.91) FLT3RETROS1EML4ALK
SCHEMBL22652336 0.90 FLT3 (0.89) FLT3RETROS1EML4ALK
SCHEMBL21455071 0.90 FLT3 (0.89) FLT3RETROS1EML4ALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3949952-B1 PHARMACEUTICAL COMPOSITION ASTELLAS PHARMA INC (JP) 2024-07-17 — — EP claimed
US-11944620-B2 Stable pharmaceutical composition for oral administration ASTELLAS PHARMA INC. (JP) 2024-04-02 — — US claimed
US-11938131-B2 Stable pharmaceutical composition for oral administration ASTELLAS PHARMA INC. (JP) 2024-03-26 — — US claimed
US-11938130-B2 Stable pharmaceutical composition for oral administration ASTELLAS PHARMA INC. (JP) 2024-03-26 — — US claimed
US-11938132-B2 Stable pharmaceutical composition for oral administration ASTELLAS PHARMA INC. (JP) 2024-03-26 — — US claimed
US-11938133-B2 Stable pharmaceutical composition for oral administration ASTELLAS PHARMA INC. (JP) 2024-03-26 — — US claimed
US-11925638-B2 Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient ASTELLAS PHARMA INC. (JP) 2024-03-12 — — US claimed
US-20230310422-A1 STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION ASTELLAS PHARMA INC. (JP) 2023-10-05 — — US claimed
US-20230301992-A1 STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION ASTELLAS PHARMA INC. (JP) 2023-09-28 — — US claimed
US-20230277530-A1 STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION ASTELLAS PHARMA INC. (JP) 2023-09-07 — — US claimed
US-20230277529-A1 STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION ASTELLAS PHARMA INC. (JP) 2023-09-07 — — US claimed
US-20230277531-A1 STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION ASTELLAS PHARMA INC. (JP) 2023-09-07 — — US claimed
US-20230277532-A1 STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION ASTELLAS PHARMA INC. (JP) 2023-09-07 — — US claimed
CN-116509866-A Use of diamino heterocyclic carboxamide compounds 安斯泰来制药株式会社 2023-08-01 — — CN claimed
EP-3318259-B1 STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION ASTELLAS PHARMA INC (JP) 2023-01-11 — — EP claimed
US-20220152020-A1 PHARMACEUTICAL COMPOSITION ASTELLAS PHARMA INC. (JP) 2022-05-19 — — US claimed
EP-3949952-A1 MEDICINAL COMPOSITION Astellas Pharma Inc. (JP) 2022-02-09 — — EP claimed
EP-3372231-B1 PHARMACEUTICAL COMPOSITION FOR CANCER IMMUNOTHERAPY PURPOSES AND/OR IMMUNOSTIMULATION PURPOSES WHICH CONTAINS DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND AS ACTIVE INGREDIENT ASTELLAS PHARMA INC (JP) 2021-09-15 — — EP claimed
EP-3103453-B1 MEDICINAL COMPOSITION COMPRISING DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND AS ACTIVE INGREDIENT ASTELLAS PHARMA INC (JP) 2020-04-01 — — EP claimed
US-12178814-B2 Pharmaceutical composition ASTELLAS PHARMA INC. (JP) 2024-12-31 — — US disclosed
EP-3949952-B1 PHARMACEUTICAL COMPOSITION ASTELLAS PHARMA INC (JP) 2024-07-17 — — EP disclosed
EP-3318259-B1 STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION ASTELLAS PHARMA INC (JP) 2023-01-11 — — EP disclosed
US-20220152020-A1 PHARMACEUTICAL COMPOSITION ASTELLAS PHARMA INC. (JP) 2022-05-19 — — US disclosed
EP-3949952-A1 MEDICINAL COMPOSITION Astellas Pharma Inc. (JP) 2022-02-09 — — EP disclosed
EP-3949952-A1 MEDICINAL COMPOSITION Astellas Pharma Inc. (JP) 2022-02-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12178814-B2 Pharmaceutical composition GCK, SNRK, GCKR FLT3 303/4885AXL 604/4885RET 727/4885
US-11938133-B2 Stable pharmaceutical composition for oral administration H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC20A1, RCC1 FLT3 2633/4885AXL 3599/4885RET 3013/4885
US-11938131-B2 Stable pharmaceutical composition for oral administration H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC1, SLC34A1 FLT3 2129/4885AXL 3294/4885RET 2525/4885
US-11925638-B2 Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient AXL, FLT3, MERTK FLT3 2/4885AXL 1/4885RET 6/4885
US-20230277531-A1 STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC20A1, RCC1 FLT3 2633/4885AXL 3599/4885RET 3013/4885
US-11938132-B2 Stable pharmaceutical composition for oral administration H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC20A1, RCC1 FLT3 2633/4885AXL 3599/4885RET 3013/4885
US-20230277530-A1 STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC20A1, RCC1 FLT3 2633/4885AXL 3599/4885RET 3013/4885
US-20230301992-A1 STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC20A1, RCC1 FLT3 2633/4885AXL 3599/4885RET 3013/4885
US-11938130-B2 Stable pharmaceutical composition for oral administration H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC20A1, RCC1 FLT3 2633/4885AXL 3599/4885RET 3013/4885
US-20230310422-A1 STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC20A1, RCC1 FLT3 2633/4885AXL 3599/4885RET 3013/4885
US-20220152020-A1 PHARMACEUTICAL COMPOSITION GCK, SNRK, GCKR FLT3 303/4885AXL 604/4885RET 727/4885
US-20230277532-A1 STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC20A1, RCC1 FLT3 2633/4885AXL 3599/4885RET 3013/4885
US-11944620-B2 Stable pharmaceutical composition for oral administration H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC20A1, RCC1 FLT3 2633/4885AXL 3599/4885RET 3013/4885
US-20230277529-A1 STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC20A1, RCC1 FLT3 2633/4885AXL 3599/4885RET 3013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback